On June 12, 2000, PerkinElmer, Inc. (NYSE: PKI) announced that it had signed a definitive agreement to acquire NEN Life Sciences, Inc., a provider of state-of-the-art drug discovery products, services and technologies to the life science industry. PerkinElmer is purchasing NEN Life Sciences from an investor group led by Genstar Capital LLC for approximately $400 million. The acquisition is anticipated to close early in the third quarter and is subject to customary closing conditions and regulatory approvals.
PerkinElmer, Inc. is a $1.7 billion high technology company based in Boston, Massachusetts, operating in four businesses - life sciences, fluid sciences, optoelectronics and analytical instruments. The company has operations in over 100 countries, and is a component of the S&P 500 index.
PerkinElmer was advised in the NEN Life Sciences acquisition by the following Hale and Dorr attorneys:
- Partners David Redlick and Hal Leibowitz, Junior Partner Rick Costello and Associates Christian Ehrbar and Dennis Sardella on corporate matters
- Partner Jorge Contreras on intellectual property matters
- Partner Rob Burke on tax matters
- Partner Bill Schmidt on employee benefits matters